Sunday 18 October 2026 Export PALI’s income statement to Excel — free account

Palisade Bio, Inc.

Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

1.41 0.13 −8.44%

Follow PALI

Alert me

Market cap: $268.4M
P/E: 2.2×
Fwd P/E: 0.0×
Dividend yield: —
F-score: n/a
Altman Z: −13.36
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.30

Total sells 0.42

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	2	—	—	—	—	—	3	—	—	1
Sell	—	—	—	2	—	—	—	—	2	—	—	—

Insider Ownership 23.97%

Capital & Financial Ratios $m

Market Cap 268.38

Revenue 0.76

Net Income (31.94)

Free Cash Flow (18.19)

Net Debt (125.17)

Current Ratio 24.26

Debt/Equity 0.00

P/E ratio 2.18

Fwd P/E 0.00

P/S ratio 394.77

P/B ratio 2.45

Past 5Y EPS Growth —

This Y EPS Growth 25.33%

Next Y EPS Growth (25.89%)

Next Y revenue growth (100.00%)

Next 5Y EPS Growth (3.67%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 55.22%

10-year low 10-year high

P/B against its own 10 years 68.09%

10-year low 10-year high

EV/Sales against its own 10 years 34.85%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	12	10	133	125
Receivables	—	—	—	1
Inventory	—	—	—	—
Other	—	—	—	—
	13	10	134	127

	2023	2024	2025	Q'26
Payables	1	1	1	2
ST’ Debt	0	0	0	—
Other	—	—	—	—
	3	3	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	(32.93%)	72.86%	(1.30%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	38.54%	0.00%	118.05%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	1	—	—	—
’23	0	—	—	—	0
’20	0	0	0	0	0
’19	0	0	0	0	0
’18	0	0	0	0	0
’17	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(8)	—	—	—
’25	(2)	(2)	(4)	(3)	(11)
’24	(3)	(3)	(3)	(2)	(12)
’23	(4)	(2)	(3)	(3)	(11)
’22	(4)	(3)	(3)	(3)	(13)
’21	(1)	(8)	(3)	(3)	(15)
’20	(2)	(1)	(1)	(2)	(5)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(8)	—	—	—
’25	(2)	(2)	(4)	(3)	(11)
’24	(3)	(3)	(3)	(2)	(12)
’23	(4)	(2)	(3)	(3)	(11)
’22	(4)	(3)	(3)	(3)	(13)
’21	(1)	(8)	(3)	(3)	(15)
’20	(2)	(1)	(1)	(2)	(5)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	(0.05)	—	—	—
’25	(0.47)	(0.58)	(0.38)	1.13	(0.30)
’24	(4.59)	(3.32)	(2.32)	(0.69)	(10.19)
’23	(8.10)	(7.95)	(7.35)	(3.75)	(26.99)
’22	(194.90)	(89.95)	(59.97)	99.62	(247.83)
’21	(1.09k)	(3.07k)	500.72	554.72	(2.54k)
’20	(4.18k)	(500.20)	(584.59)	(1.08k)	(2.79k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	222,300.00	79,200.00	25,200.00	3,150.00	2,250.00	975.00	26.10	7.50	1.38	0.53	Analyst estimates 2026–2028 Powerpack
	High	1,275,300.00	594,000.00	212,400.00	62,100.00	18,405.00	12,015.00	1,215.00	69.90	22.35	2.64
People
People	Employees	11	6	6	5	7	13	12	9	8	14
	Revenue/emp, $m	0.00	0.04	0.04	0.00	0.00	0.00	0.00	0.03	0.00	0.00
Income, $m
Income, $m	Revenue	0	0	0	0	0	—	—	0	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	(1,081.48)	0.00	0.00	100.00	—	—
	EBT	(21)	(16)	(5)	(8)	(10)	(27)	(14)	(12)	(14)	(17)
	EBT margin, %	(130,090.12)	(6,025.38)	(1,894.08)	(54,231.82)	(76,555.56)	0.00	0.00	(4,920.00)	0.00	0.00
	Net income	(21)	(16)	(5)	(8)	(10)	(27)	(14)	(12)	(14)	(17)
	Depreciation	1	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	162.00	2,600.00	2,600.00	30.80	3.65	0.00	0.00	0.55	0.00	0.00
	Earnings	(227,540.70)	(107,924.50)	(28,779.85)	(17,088.04)	(2,792.85)	(2,143.93)	(247.83)	(26.99)	(10.19)	(0.30)
	Cash flow	(156,161.00)	(134,162.00)	(76,924.00)	(14,511.40)	(1,288.65)	(1,191.37)	(227.60)	(24.41)	(8.61)	(0.19)
	Capex	(981.00)	(114.00)	(17.00)	0.00	(1.62)	0.00	(0.17)	(0.01)	0.00	0.00
	Free cash flow	(157,142.00)	(134,276.00)	(76,941.00)	(14,511.40)	(1,290.27)	(1,191.37)	(227.77)	(24.42)	(8.61)	(0.19)
	Book value	113,308.00	85,151.00	60,496.00	10,252.00	(1,918.65)	593.95	212.59	24.81	5.29	2.32
	Shares, m	0	0	0	0	0	0	0	0	1	56
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	0.00	—	—
	P/S	2,238.89	70.27	10.73	144.64	1,085.33	—	—	15.41	—	—
	P/B	3.20	2.15	0.46	0.43	0.00	—	—	0.35	—	—
	EV/Sales	1,378.22	44.89	8.00	(175.75)	1,117.04	—	—	(31.89)	—	—
	EV/FCF	(1.42)	(0.87)	(0.27)	0.37	(3.16)	—	—	0.74	—	—
Cash, $m
Cash, $m	Operating cash flow	(16)	(13)	(8)	(7)	(5)	(15)	(13)	(11)	(12)	(11)
	Capex	0	0	0	—	0	—	0	0	—	—
	Free cash flow	(16)	(13)	(8)	(7)	(5)	(15)	(13)	(11)	(12)	(11)
Balance, $m
Balance, $m	Working capital	14	11	5	4	(7)	9	12	11	7	130
	Total debt	4	—	—	0	1	0	0	0	0	0
	Net debt	(16)	(12)	(6)	(5)	0	(10)	(12)	(12)	(10)	(133)
	Shareholders’ equity	11	9	6	5	(7)	7	12	11	7	129
Returns, %
Returns, %	ROA	(112.24)	(85.87)	(45.66)	(117.07)	(214.98)	(342.75)	(100.87)	(82.62)	(115.82)	(23.11)
	ROIC	0.00	0.00	(1,966.55)	(2,809.80)	0.00	0.00	(5,340.01)	0.00	0.00	0.00
	ROE	(258.77)	(158.04)	(67.72)	(149.62)	179.86	576.17	(143.75)	(103.55)	(153.59)	(24.52)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OCGN Ocugen, Inc.	$275.9M	— (loss-making)	— (loss-making)	+8.38% (above 0%: growing)	n/m	−13.42% (below 0%: shrinking)	100.00%	(1,105.11%)	Compare
NAUT Nautilus Biotechnology, Inc.	$274.9M	— (loss-making)	—	—	n/m	−3.16% (below 0%: shrinking)	92.11%	(8,296.32%)	Compare
IPSC Century Therapeutics, Inc.	$271.6M	— (loss-making)	— (loss-making)	+12,667.72% (above 0%: growing)	n/m	+26.66% (above 0%: growing)	100.00%	0.00%	Compare
EYPT EyePoint, Inc.	$270.7M	— (loss-making)	— (loss-making)	−90.49% (below 0%: shrinking)	n/m	+0.41% (above 0%: growing)	100.00%	(19,207.10%)	Compare
PALI Palisade Bio, Inc.	$268.4M	2.2×	— (loss-making)	+19,900.00% (above 0%: growing)	n/m	−318.44% (below 0%: shrinking)	100.00%	(2,339.60%)
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
PRLD Prelude Therapeutics Incorporated	$265.0M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)	Compare
Median of peers	$268.3M	—	—	+133.87%	—	+7.09%	96.06%	(228.53%)

All 614 Biotechnology stocks →

Palisade Bio, Inc. (PALI) key facts

Palisade Bio, Inc. (PALI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00.
As of October 16, 2026, PALI traded at $1.41, a market capitalization of $268.4 million.
Return on equity was −24.5% and debt-to-equity 0.00.
Its Altman Z-score is −13.36 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.